Cognitive Behavioral Therapy to Sustain the Antidepressant Effects of Ketamine in Treatment-Resistant Depression: A Randomized Clinical Trial.
Samuel T Wilkinson, Taeho Greg Rhee, Jutta Joormann...
https://pubmed.ncbi.nlm.nih.gov/34186531/Actively Recruiting
Led by University of Puerto Rico · Updated on 2026-01-27
20
Participants Needed
2
Research Sites
N/A
Total Duration
Researchers are evaluating the effects of esketamine Spravato, an FDA-approved nasal spray, on adults with treatment-resistant depression TRD. The study aims to determine if adding therapeutic support sessions before and after esketamine doses can improve mood, functioning, and overall treatment experience. This is a randomized controlled trial comparing esketamine with and without these additional support sessions. All participants will receive intranasal esketamine twice weekly during an acute 4-week phase, then weekly or biweekly during a maintenance phase lasting up to 8 weeks based on clinical response. One group will also receive brief, structured preparation and integration therapy sessions before and after each dose, designed to support emotional processing and meaning-making. The other group will receive standard clinical monitoring without extra psychotherapeutic support. During the 8-week study, participants will attend dosing sessions with monitoring for at least two hours after each dose. Researchers will assess depression severity using the Montgomery-sberg Depression Rating Scale MADRS along with measures of emotional regulation, treatment acceptability, and safety. Follow-up assessments will monitor treatment response, remission, relapse, and suicidal thoughts. The study is conducted under clinical supervision with informed consent and ethical approval.
CONDITIONS
Esketamine With or Without Integration Therapy for Treatment-Resistant Depression
P
Paulina D Rullan-Farinacci, MD
K
Karen G Martinez-Gonzalez, MD, MSc
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Puerto Rico
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 8 weeks
Participants receive FDA-approved intranasal esketamine twice weekly during the first 4 weeks (acute phase), then weekly or biweekly during weeks 5 to 8 (maintenance phase). Participants in the integration arm also receive brief, structured therapeutic preparation and integration sessions before and after each dosing to support emotional processing and meaning-making.
Twice-weekly visits for 4 weeks, then weekly or biweekly visits for 4 weeks
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Samuel T Wilkinson, Taeho Greg Rhee, Jutta Joormann...
https://pubmed.ncbi.nlm.nih.gov/34186531/Jennifer Dore, Brent Turnipseed, Shannon Dwyer...
https://pubmed.ncbi.nlm.nih.gov/30917760/Ella J Daly, Madhukar H Trivedi, Adam Janik...
https://pubmed.ncbi.nlm.nih.gov/31166571/Carla M Canuso, Jaskaran B Singh, Maggie Fedgchin...
https://pubmed.ncbi.nlm.nih.gov/29656663/Vanina Popova, Ella J Daly, Madhukar Trivedi...
https://pubmed.ncbi.nlm.nih.gov/31109201/Ingmar Gorman, Elizabeth M Nielson, Aja Molinar...
https://pubmed.ncbi.nlm.nih.gov/33796055/University of Puerto Rico
Lead Sponsor